Reports
Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market: By Cell Type: B-cell ALL, T-cell ALL, Philadelphia Chromosome: Positive (Ph+) and negative (Ph-) ALL; By Therapy Type: Chemotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation; Regional Analysis; Competitive Landscape; 2024-2032
Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Outlook
The global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market attained a value of USD 2.79 billion in 2023. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of 4.60% to reach USD 4.19 billion by 2032.
-therapeutics-market.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The rising occurrence of acute lymphoblastic leukaemia (ALL) and the growing initiatives by public and private organisations are among the key factors anticipated to drive the market growth.
Market Segmentation
The acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics industry can be broadly categorised based on cell type and therapy type.
-therapeutics-market-by-therapy-type.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on cell type, the market is segmented into:
- B-Cell ALL
- T-Cell ALL
- Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL
Based on the therapy type, the market is divided into:
- Chemotherapy
- Hyper- CVAD Regimen
- CALGB 8811 Regimen
- Linker Regimen
- Nucleoside Inhibitors
- Others
- Targeted Therapy
- Radiation Therapy
- Stem Cell Transplantation
The EMR report looks into the regional markets of acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
-therapeutics-market-by-region.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The technological progress made in the identification of infected cells is a significant market growth driver. Due to factors such as the capacity to kill leukaemia cells and the prevention of the growth and proliferation of cancer, the chemotherapy segment was leading the market in 2020. Due to the growing prevalence in adults, the B-cell ALL type is projected to be the fastest-growing category in the industry. With the release of Besponsa (inotuzumab ozogamicin) and pipeline drugs such as eryaspase (asparaginase), the United States is anticipated to witness a significant growth in the industry in the coming years.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics industry, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Erytech Pharma
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Others
The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Cell Type, Therapy Type, Region |
| Breakup by Cell Type | B-cell ALL, T-cell ALL, Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL |
| Breakup by Therapy Type | Chemotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Bristol-Myers Squibb Company, Eisai Co., Ltd., Erytech Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market (2018-2023)
8.3 Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast (2024-2032)
8.4 Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market by Cell Type
8.4.1 B-cell ALL
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 T-cell ALL
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Philadelphia Chromosome: Positive (Ph+) and negative (Ph-) ALL
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.5 Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market by Therapy Type
8.5.1 Chemotherapy
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.1.3 Breakup by Chemotherapy Type
8.5.1.3.1 Hyper-CVAD Regimen
8.5.1.3.2 CALGB 8811 Regimen
8.5.1.3.3 Linker Regimen
8.5.1.3.4 Nucleoside Inhibitors
8.5.1.3.5 Others
8.5.2 Targeted Therapy
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Radiation Therapy
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Stem Cell Transplantation
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.6 Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market by Region
8.6.1 North America
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Europe
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Asia Pacific
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 Latin America
8.6.4.1 Historical Trend (2018-2023)
8.6.4.2 Forecast Trend (2024-2032)
8.6.5 Middle East and Africa
8.6.5.1 Historical Trend (2018-2023)
8.6.5.2 Forecast Trend (2024-2032)
9 North America Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.2 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Bristol-Myers Squibb Company
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Eisai Co., Ltd.
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Erytech Pharma
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 F. Hoffmann-La Roche Ltd
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Pfizer Inc.
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market: Key Industry Highlights, 2018 and 2032
2. Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Cell Type (USD Billion), 2018-2023
3. Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Cell Type (USD Billion), 2024-2032
4. Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Therapy Type (USD Billion), 2018-2023
5. Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Therapy Type (USD Billion), 2024-2032
6. Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Region (USD Billion), 2018-2023
7. Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Region (USD Billion), 2024-2032
8. North America Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Country (USD Billion), 2018-2023
9. North America Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Country (USD Billion), 2024-2032
10. Europe Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Country (USD Billion), 2018-2023
11. Europe Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Asia Pacific Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Asia Pacific Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Latin America Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Latin America Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Structure
Key Questions Answered in the Report
In 2023, the global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market attained a value of nearly USD 2.79 billion.
The market is projected to grow at a CAGR of 4.60% between 2023 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach about USD 4.19 billion by 2032.
The major drivers of the industry, such as the growing incidences of acute lymphoblastic leukaemia, initiatives by various public and private organisations to create awareness among people, growing R&D activities, and rapid technological advancements, are expected to aid the market growth.
The development of inotuzumab ozogamicin (Besponsa) and pipeline drugs is the key market trend guiding the growth of the industry.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
B-cell ALL, T-cell ALL, and Philadelphia chromosome- positive (Ph+) and -negative (Ph-) ALL are the significant cell types of acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics in the industry.
Chemotherapy segment is the leading therapy type in the market.
The major players in the industry are Bristol-Myers Squibb Company, Eisai Co., Ltd., Erytech Pharma, F. Hoffmann-La Roche Ltd, and Pfizer Inc., among others.
Analyst Review
The global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market attained a value of USD 2.79 billion in 2023, driven by the growing cases of acute lymphoblastic leukaemia and increased clinical trials. Aided by the development of inotuzumab ozogamicin, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 4.60%. The industry is projected to reach USD 4.19 billion by 2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on cell type, the industry can be segmented into B-cell ALL, T-cell ALL, and Philadelphia chromosome- positive (Ph+) and -negative (Ph-) ALL. On the basis of therapy, the chemotherapy segment accounts for the leading share in the industry. The major regional markets for acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bristol-Myers Squibb Company, Eisai Co., Ltd., Erytech Pharma, F. Hoffmann-La Roche Ltd, and Pfizer Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER